Navitor develops first-in-class small-molecule therapeutics that selectively modulate mTORC1 signaling to restore normal cellular responses to nutrients and growth factors. Its pipeline includes candidates designed to either increase or decrease nutrient- and growth factor–responsive pathways, targeting metabolic, neurodegenerative, immune/autoimmune, musculoskeletal and several rare disorders, as well as age-related immune suppression. The company’s drug discovery platform is built on foundational discoveries related to mTORC1 and nutrient signaling by Dr. David Sabatini at The Whitehead Institute. Navitor intends to advance a lead program into clinical trials to demonstrate initial efficacy and safety and will continue developing additional pipeline candidates while augmenting its proprietary discovery platform. The company is headquartered in Cambridge, Mass., and is backed by a syndicate of corporate and financial investors. Recent financing activity (Series B) strengthens its near-term ability to fund clinical advancement and continued discovery work. Navitor is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling via the mTORC1 pathway. Its core product is a proprietary drug discovery platform designed to create first-in-class selective modulators of mTORC1, aimed at precise modulation of protein synthesis and cellular growth. The company intends to use its platform to generate therapeutics that can either "turn up" or "turn down" nutrient-responsive pathways to restore normal mTORC1 function across multiple indications. Navitor plans to augment its platform and further develop proprietary technologies, tools and assays to address the complexity of mTORC1 signaling. Navitor's founding intellectual property is based on discoveries by David M. Sabatini at the Whitehead Institute, to which it has exclusive access. The company recently closed a $23.5 million Series A to accelerate pipeline development, and is backed by Polaris Partners, Atlas Venture, Johnson & Johnson Development Corporation, SR One and The Longevity Fund. Navitor is based in Cambridge, Mass.

Total raised

$57M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2015